💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadExplore for free

BRIEF-Takeda Pharmaceutical & Ovid Therapeutics announces clinical development,commercialization collaboration for TAK-935

Published 2017-01-18, 07:15 a/m
© Reuters.  BRIEF-Takeda Pharmaceutical & Ovid Therapeutics announces clinical development,commercialization collaboration for TAK-935

Jan 18 (Reuters) - Takeda Pharmaceutical Co Ltd:

* Takeda and Ovid Therapeutics announce innovative clinical development, commercialization collaboration for TAK-935 in rare pediatric epilepsies

* Takeda Pharmaceutical says received equity in Ovid and may be eligible to receive certain milestone payments based on the advancement of TAK-935

* Takeda Pharmaceutical says Takeda will lead commercialization in Japan, and has the option to lead in asia and other selected geographies

* Takeda Pharmaceutical says Cos to share in development and commercialization costs on 50/50 basis; if successful, will share in profits on 50/50 basis

* Takeda Pharmaceutical says if mutually agreed, additional orphan central nervous system indications may also be pursued

* Takeda Pharmaceutical says Ovid will lead clinical development activities and commercialization of TAK-935 in the U.S., Europe, Canada and Israel

* Takeda pharmaceutical says additional financial details were not disclosed

* Takeda pharmaceutical says companies expect to initiate a phase 1B/2A study in 2017 in patients with rare epileptic encephalopathies Source text for Eikon: ID:nNDL98gtgj Further company coverage: 4502.T

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.